Protalix Biotherapeutics (NYSEAMERICAN:PLX) received a $3.00 price target from HC Wainwright in a report issued on Friday, TipRanks reports. The firm currently has a “buy” rating on the stock.

Separately, Zacks Investment Research upgraded Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th.

Shares of PLX stock traded down $0.03 during mid-day trading on Friday, hitting $0.29. The stock had a trading volume of 3,993,193 shares, compared to its average volume of 556,246. Protalix Biotherapeutics has a 12-month low of $0.17 and a 12-month high of $0.60.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last issued its earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.02). The business had revenue of $12.25 million during the quarter, compared to analyst estimates of $11.75 million. During the same period last year, the company earned ($0.08) EPS.

A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Renaissance Technologies LLC increased its stake in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 7.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,326,528 shares of the company’s stock after purchasing an additional 308,823 shares during the quarter. Renaissance Technologies LLC owned approximately 2.92% of Protalix Biotherapeutics worth $2,029,000 as of its most recent SEC filing.

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Featured Story: What is a blue-chip stock?

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with's FREE daily email newsletter.